Literature DB >> 6111700

Phenformin-induced lacticacidosis associated with impaired debrisoquine hydroxylation.

N S Oates, R R Shah, J R Idle, R L Smith.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6111700     DOI: 10.1016/s0140-6736(81)92711-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  9 in total

1.  Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect.

Authors:  C Funck-Brentano; H K Kroemer; H Pavlou; R L Woosley; D M Roden
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

Review 2.  Assessment of the drug metabolism capacity of the liver.

Authors:  B K Park
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

Review 3.  The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs.

Authors:  R E Ferner; S Chaplin
Journal:  Clin Pharmacokinet       Date:  1987-06       Impact factor: 6.447

4.  The genetic control of phenformin 4-hydroxylation.

Authors:  R R Shah; D A Evans; N S Oates; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1985-10       Impact factor: 6.318

5.  In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme.

Authors:  N A Helsby; S A Ward; R E Howells; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

6.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

7.  Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine.

Authors:  M Eichelbaum; L Bertilsson; J Säwe
Journal:  Br J Clin Pharmacol       Date:  1983-03       Impact factor: 4.335

Review 8.  Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

9.  Impaired oxidation of debrisoquine in patients with perhexiline neuropathy.

Authors:  R R Shah; N S Oates; J R Idle; R L Smith; J D Lockhart
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.